Unicycive Therapeutics (UNCY) News and press releases

12 Health Care Stocks Moving In Wednesday's After-Market Session

4 May 22

Movers

Gainers 1Life Healthcare (NASDAQ:ONEM) shares moved upwards by 22.4% to $9.58 during Wednesday's after-market session. The market value of their outstanding shares is at $1.8 billion. The company's, Q1 earnings came out today.

12 Health Care Stocks Moving In Monday's After-Market Session

2 May 22

Movers

Gainers

12 Health Care Stocks Moving In Wednesday's After-Market Session

27 Apr 22

Movers

Gainers Unicycive Therapeutics (NASDAQ:UNCY) shares moved upwards by 9.9% to $1.0 during Wednesday's after-market session. The company's market cap stands at $15.0 million.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

29 Mar 22

Movers

Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 45.0% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $8.5 million.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

17 Mar 22

Pre-Market Outlook, Markets, Movers

22 Stocks Moving in Thursday's Pre-Market Session

17 Mar 22

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers TD Holdings, Inc. (NASDAQ: GLG) rose 81.2% to $0.43 in pre-market trading after the company reported FY21 results.

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022

16 Mar 22

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Upgrades

Unicycive Announces Acceptance Of Two Preclinical Data Sets To Be Presented At The European Renal Association Congress

16 Mar 22

News, FDA, Events

Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that two in-vivo data sets highlighting the

Maxim Group Initiates Coverage On Unicycive Therapeutics with Buy Rating, Announces Price Target of $3

16 Mar 22

News, Price Target, Initiation, Analyst Ratings

Maxim Group analyst Jason McCarthy initiates coverage on Unicycive Therapeutics (NASDAQ:UNCY) with a Buy rating and announces Price Target of $3.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

15 Mar 22

Pre-Market Outlook, Markets, Movers

Stocks That Hit 52-Week Lows On Tuesday

8 Mar 22

News, Options, Intraday Update, Markets, Movers, Trading Ideas

Tuesday's session saw 729 companies set new 52-week lows.

12 Health Care Stocks Moving In Thursday's After-Market Session

24 Feb 22

Movers

Gainers Unicycive Therapeutics (NASDAQ:UNCY) shares rose 27.9% to $1.65 during Thursday's after-market session. The company's market cap stands at $24.7 million.

Glancy Prongay & Murray LLP Announces Investigation of Unicycive Therapeutics, Inc.

14 Apr 22

Press Releases

Glancy Prongay & Murray LLP ("GPM") announces its investigation of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) concerning the Company and its directors' and officers' possible violations of state laws. If you own

Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney Diseases

14 Apr 22

News, Health Care, Press Releases

LOS ALTOS, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that there

Unicycive To Ring the Nasdaq Closing Bell on March 29, 2022

23 Mar 22

News, Markets, Press Releases

LOS ALTOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that the

Unicycive Announces Acceptance of Two Preclinical Data Sets to be Presented at the European Renal Association Congress

16 Mar 22

News, Press Releases

LOS ALTOS, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that two

Unicycive to Present at Upcoming March Investor Conferences

3 Mar 22

Press Releases

LOS ALTOS, Calif., March 3, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh